Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.
Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.